CIRM Awards Seek to Move Cell Therapies to the Clinic

摘要

Five years after it launched, the California Institute for Regenerative Medicine (CIRM) last week awarded its first disease-oriented grants-$230 million to 14 teams-intended to speed stem cell therapies to patients. In seeming contrast to its original mission, only about one-third of the 4-yearrngrants involve research using embryonic stem (ES) cells. The state created CIRM largely to fund ES cell research, which was lagging because of Bush-era restrictions on the controversial technology.